Compass Therapeutics Stock (NASDAQ:CMPX)
Previous Close
$3.22
52W Range
$0.77 - $3.63
50D Avg
$1.76
200D Avg
$1.51
Market Cap
$427.90M
Avg Vol (3M)
$1.21M
Beta
0.75
Div Yield
-
CMPX Company Profile
Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases. The company's product candidates in the clinical stage of development include CTX-009, an investigational bispecific antibody that blocks Delta-like ligand 4/Notch and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137. Its product candidates also comprise CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1. The company was founded in 2014 and is headquartered in Boston, Massachusetts.
CMPX Performance
Peer Comparison
| Ticker | Company |
|---|---|
| IDYA | IDEAYA Biosciences, Inc. |
| GOSS | Gossamer Bio, Inc. |
| ELVN | Enliven Therapeutics, Inc. |
| KRON | Kronos Bio, Inc. |
| PRTC | PureTech Health plc |
| MGTX | MeiraGTx Holdings plc |
| ANAB | AnaptysBio, Inc. |
| LYRA | Lyra Therapeutics, Inc. |
| KROS | Keros Therapeutics, Inc. |
| NAMS | NewAmsterdam Pharma Company N.V. |
| GLUE | Monte Rosa Therapeutics, Inc. |
| TYRA | Tyra Biosciences, Inc. |
| GPCR | Structure Therapeutics Inc. |
| IVA | Inventiva S.A. |
| REPL | Replimune Group, Inc. |
| VIGL | Vigil Neuroscience, Inc. |
| CGEM | Cullinan Oncology, Inc. |
| AVTE | Aerovate Therapeutics, Inc. |
| MLTX | MoonLake Immunotherapeutics |
| NVCT | Nuvectis Pharma, Inc. |
| PEPG | PepGen Inc. |